欧洲翼状胬肉药物市场，按疾病类型（进行性翼状胬肉和萎缩性翼状胬肉）、分期（第 2 期、第 3 期、第 1 期、第 4 期）、治疗（人工泪液/外用润滑剂和类固醇眼药水）、配方（眼药水、眼药膏等）、购买方式（处方药和非处方药 (OTC)）、人群类型（老年人和成人）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（零售药店、医院药店、网上药店等）划分 - 行业趋势和预测到 2029 年。
市场分析和见解
胸膜外膜(Pterygium)是一种常见的外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外 它以希腊语单词pterygos来命名,意为"翼". 损伤发生在鼻肢上的时间比具有一具有特征的翅膀外观的时间更频繁. 紫外线暴露与白血病的发生密切相关。 具有紫外线接触高历史的个人和生活在赤道附近的个人的发生率较高(室外工作)。 根据某些研究,男性的发病率略高于女性,这可能是由于紫外线暴露率较高所致.
它能引起出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出入出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出出 它可能影响一双眼睛。
Pterygium被诊断出使用显微镜在全眼检查时检查眼部前部成分,并基于从眼部白色区域看角膜上组织生长的外观.
Data Bridge Market Research分析认为,全球欧洲肽类药物市场将在2022-2029年的预测期间以4.8%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020年(可算作2019-2014年) |
|
数量单位 |
收入(百万美元),定价(美元) |
|
覆盖部分 |
疾病类型(渐进性肽和营养性肽)、阶段(第2阶段、第3阶段、第1阶段、第4阶段)、治疗(人工眼泪/营养润滑剂和类固醇眼滴)、配方(眼滴、眼膏等)、购买方式(处方和柜台(OTC)、人口类型(产科和成人)、最终用户(医院、专科诊所、家庭保健等)、分发渠道(零售药房、医院药房、在线药房等) |
|
涵盖国家 |
俄罗斯、西班牙、土耳其、德国、意大利、联合王国、法国、匈牙利、奥地利、瑞士、荷兰、波兰、爱尔兰、挪威、立陶宛、欧洲其余地区 |
|
覆盖的市场玩家 |
Johnson & Johnson Services, Inc.(美国)、Novartis AG(瑞士)、Akorn 运营公司有限责任公司(美国)、Bausch & Lomb Incorporated(加拿大)、AbbVie Inc.(美国)、Prestige 消费者保健公司(美国)、Théa实验室(法国)、Wellona Pharma(印度)、SAGER PHARMA(匈牙利)、Sylentis(西班牙)、Bayer AG(德国)、Zydus集团、Amneal 医药有限责任公司(印度)、OASIS医疗公司(美国)、Similasan公司(瑞士)、Alcon(瑞士)和Santen 医药有限公司(日本) |
市场定义
胸膜外膜(Pterygium)是一种常见的外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外膜外 它以希腊语单词pterygos来命名,意为"翼". 损伤发生在鼻肢上的时间比具有一具有特征的翅膀外观的时间更频繁. 紫外线暴露与白血病的发生密切相关。 具有紫外线接触高历史的个人和生活在赤道附近的个人的发生率较高(室外工作)。 根据某些研究,男性的发病率略高于女性,原因可能只是紫外线暴露率较高.
Pterygium被诊断出使用显微镜在全眼检查时检查眼部前部成分,并基于从眼部白色区域看角膜上组织生长的外观.
欧洲药市场动态
本节讨论了解市场驱动力、优势、机会、制约因素和挑战。 下文详细讨论所有这些问题:
司机
- 眼科疾病发病率和流行率的上升
根据2021年国家医学图书馆(英语:National Centre for Biology Information)所公布的数据,各地的流行率相差悬殊. 其最丰富的是卡梅伦的"pt带",它贯穿于赤道南北37°之间.
t最常见的病因包括长期受太阳所发出的紫外线(UV)光照射(最常见的病因)和由炎热,干燥的天气,风和尘埃所引起眼睛刺激. 肯定因素表明,这是全球白喉药物市场的主要驱动力。
- 老年人口的增加
随着全球老年病人口的增长,视力疾病严重视力疼痛的流行也正在增长. 根据在"2020年全球盲目程度和距离及近视障碍:实现2020年愿景目标的进展和前景"(ARVO)上公布的数据,"视觉与眼科研究协会"估计有4,190万人失明.
随着人口的增长,保健系统的压力正在增加。 对护理和服务的需求正在增加,以治疗眼膜障碍,包括白喉。 因此,老年人口的增长是欧洲白喉药物市场的一个大机会。
机会
-
减轻眼病负担的方案和举措
预防失明的国际机构与声望很高的非政府组织和公司发起了若干方案和倡议,以提高认识并减轻眼病的负担。
比如说,
-
国际机构赞同我们的儿童展望,以及由布赖恩·霍尔登展望研究所和生命展望基金(由Essilor创建)共同发起的预防失明倡议。
限制/挑战
各种眼科疾病日益普遍,也增加了及时治疗的必要性。 然而,眼科疾病的治疗和适当药物价格并不高。 最近的研究表明,在过去几年里,热门类固醇的价格正在上升。 尽管一些热门眼科类固醇如先德尼索隆等价格略为低廉,但其他先进的药物和滴眼药依然昂贵.
欧洲百灵药市场报告详细介绍了近期新发展,贸易监管,进出口分析,生产分析,价值链优化,市场份额,国内及本地化市场主体的影响等,分析了新兴收入口号,市场监管变化,战略性市场增长分析,市场规模,类别市场增长,应用优势和主导地位,产品审批,产品推出,地域扩张,市场技术创新等方面的机会. 为了获得更多关于Pterygium药物市场的信息,联系Data Bridge Market Research for a Analysis Brief. 我们的团队将帮助你做出知情的市场决定,以实现市场增长.
患者流行病学分析
由于化学工业的兴起和世界范围的污染,眼科病的流行继续呈现出快速增长. 化学烧伤和闪光烧伤由于眼睛表面受刺激而引起显著而严重的外观疼痛.
根据2021年国家医学图书馆(英语:National Centre for Biology Information)所公布的数据,各地的流行率相差悬殊. 其最丰富的是卡梅伦的"pt带",它贯穿于赤道南北37°之间. 据报告,全世界白喉的流行率从0.3%到29%不等。
欧洲肽类药物市场也提供详细的市场分析,用于病人分析,预后和治愈. 报告提供的一些数据变量包括流行率、发生率、死亡率和遵守率。 对流行病学对市场增长的直接或间接影响分析进行了分析,为预测增长时期的市场创造了更有力和共性多变的统计模型。
COVID-19后对欧洲Pterygium药物市场的影响
COVID-19对市场产生了负面影响. 大流行病期间的封锁和隔离使疾病管理和药物坚持情况复杂化。 缺乏常规治疗和药品管理的保健设施将进一步影响市场。
最近的发展
2021年4月,阿尔康宣布在美国推出Systane水合多剂量防腐剂无润滑眼滴. 该产品是患有水分不足干眼的患者的一种新选择,并起到保护剂的作用来进一步缓解眼部的刺激和干燥. 这帮助公司增加了投资组合
欧洲药市场范围
根据疾病类型、阶段、治疗、配方、购买方式、人口类型、最终用户和分销渠道,欧洲白喉药物市场分为八个值得注意的部分。 这些部门的增长将有助于你分析这些行业的微弱增长部门,并为用户提供宝贵的市场概况和市场见解,帮助他们作出确定核心市场应用的战略决定。
疾病类型
- 渐进式
- 营养性 P
基于疾病,欧洲肽类药物市场被分化为进步肽和萎缩肽.
阶段
- 第1阶段
- 第2阶段
- 第3阶段
- 第4阶段
根据阶段,欧洲的t药市场被分入了阶段一,阶段二,阶段三和阶段四.
治疗
- 人造眼泪/热带润滑剂
- 类固醇眼滴
基于治疗,欧洲肽类药物市场被分入人造眼泪/专题润滑剂和类固醇眼滴.
拟订
- 眼泪滴出
- 眼膏
- 其他人员
根据配方,欧洲t类药物市场被分解为眼滴,膏等.
采购方式
- 处方
- 过柜台(OTC)
根据购买方式,欧洲的t药市场被分割成处方和场外(OTC).
人口类型
- 老年病
- 成年人
根据人口类型,欧洲百合药物市场被分割为老年和成年人.
最终用户
- 医院
- 专科诊所
- 家庭保健
- 其他人员
根据最终用户情况,欧洲白喉药物市场分为医院、专科诊所、家庭保健等。
分发频道
- 零售药店
- 医院药房
- 在线药店
- 其他人员
根据分销渠道,欧洲t药市场被分入零售药店,医院药店和在线药店.
欧洲苯丙胺药物市场区域分析/观察
分析欧洲t药市场,按国家、疾病类型、阶段、治疗、配方、购买方式、人口类型、最终用户和分销渠道提供市场规模的见解和趋势。 见上文。
欧洲药市报告涵盖的国家有:俄罗斯、西班牙、土耳其、德国、意大利、联合王国、法国、匈牙利、奥地利、瑞士、荷兰、波兰、爱尔兰、挪威、立陶宛、欧洲其他地区。
由于眼科疾病日益普遍,对眼科疾病治疗的认识也不断提高,欧洲肽类药物市场预计会增长.
预计俄罗斯将在市场份额和收入方面主宰欧洲的百合药市场,并将在预测期间继续繁荣其支配地位。 这是由于大量人口患有白喉。
报告的国家部分还提供了个别市场影响因素和影响市场当前和未来趋势的市场监管变化。 数据点,如新的和替换销售、国家人口统计和进出口关税,是用来预测个别国家市场情况的一些主要指针。 此外,在对国家数据进行预测分析的同时,还考虑了全球品牌的存在和可得性及其由于来自当地和国内品牌的高度竞争而面临的挑战以及销售渠道的影响。
竞争性景观与欧洲药材市场份额分析
欧洲百合药物市场竞争景观提供了竞争对手的细节. 详情包括公司概况,公司财务,创收,市场潜力,研发投资,新市场举措,欧洲存在,生产地点和设施,生产能力,公司优势和弱点,产品推出,产品宽度和广度,应用优势等. 上述数据点仅涉及公司对白喉药物市场的关注。
在全球欧洲药市场运营的一些主要角色有:强生和强生服务公司,诺华AG,Akorn运营公司有限责任公司,Bausch & Lomb Incorted,AbbVie Inc.,Prestige消费者保健公司,Théa实验室,Wellona Pharma,SAGER PHARMA,Sylentis,Bayer AG,Zydus Group,Amneal药品有限责任公司,OASIS Medical,Similasan Corporation,Alcon等.
研究方法
数据收集和基准年分析使用具有大样本规模的数据收集模块。 利用市场统计和连贯一致的模式分析和估计市场数据。 此外,市场份额分析和主要趋势分析是市场报告的主要成功因素. DBMR研究小组使用的关键研究方法是数据三角化,涉及数据挖掘、数据变量对市场的影响分析以及初级(行业专家)验证。 除此之外,数据模型还包括供应商定位网格,市场时间线分析,市场概况和指南,公司定位网格,公司市场份额分析,计量标准,欧洲Vs区域,和供应商份额分析. 如有进一步调查,请致电分析员。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE PTERYGIUM DRUG MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CLASS SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL'S MODEL
4.2 PORTER'S 5 FORCES
4.3 EUROPE PTERYGIUM DRUG MARKET: NUMBER OF SURGERIES
5 EPIDEMIOLOGY
6 PIPELINE ANALYSIS
7 EUROPE PTERYGIUM DRUG MARKET: REGULATIONS
7.1 REGULATION IN THE U.S.
7.2 REGULATION IN EUROPE:
7.3 REGULATIONS IN CHINA:
7.4 REGULATIONS IN INDIA:
7.5 RELEVANT ACTS FOR THIS FRAMEWORK:
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN INCIDENCES AND PREVALENCE OF OPHTHALMIC DISORDERS
8.1.2 RISE IN GERIATRIC POPULATION
8.1.3 INCREASE IN HEALTHCARE AWARENESS TO REDUCE THE RISK OF EYE ILLNESSES
8.2 RESTRAINTS
8.2.1 HIGH COST OF EYE TREATMENT AND MEDICATION
8.2.2 SIDE EFFECTS OF STEROIDS EYE DROPS
8.3 OPPORTUNITIES
8.3.1 PROGRAMS AND INITIATIVES TO REDUCE THE BURDEN OF EYE DISEASES
8.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME
8.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES
8.4 CHALLENGES
8.4.1 STRINGENT RULES & REGULATIONS
8.4.2 EXPOSURE TO ULTRAVIOLET RADIATIONS
9 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE
9.1 OVERVIEW
9.2 PROGRESSIVE PTERYGIUM
9.3 ATROPHIC PTERYGIUM
10 EUROPE PTERYGIUM DRUG MARKET, BY STAGES
10.1 OVERVIEW
10.2 STAGE 2
10.3 STAGE 3
10.4 STAGE 1
10.5 STAGE 4
11 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS
11.2.1 DEMULCENT
11.2.2 EMOLLIENTS
11.3 STEROID EYE DROPS
11.3.1 KETONE STEROIDS
11.3.1.1 PREDNOSOLONE
11.3.1.2 DEXAMETHASONE
11.3.1.3 FLUROMETHOLONE
11.3.1.4 OTHERS
11.3.2 ESTER STEROID (LOTERPREDNOL)
12 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION
12.1 OVERVIEW
12.2 EYE DROPS
12.2.1 EYE DROPS WITH PRESERVATIVES
12.2.2 PRESERVATIVE-FREE EYE DROPS
12.3 EYE OINTMENTS
12.4 OTHERS
13 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE
13.1 OVERVIEW
13.2 PRESCRIPTION
13.3 OVER THE COUNTER (OTC)
14 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE
14.1 OVERVIEW
14.2 GERIATRIC
14.3 ADULTS
15 EUROPE PTERYGIUM DRUG MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECIALTY CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACIES
16.3 HOSPITAL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 EUROPE PTERYGIUM DRUG MARKET, BY REGION
17.1 EUROPE
17.1.1 RUSSIA
17.1.2 SPAIN
17.1.3 TURKEY
17.1.4 GERMANY
17.1.5 ITALY
17.1.6 U.K.
17.1.7 FRANCE
17.1.8 HUNGARY
17.1.9 AUSTRIA
17.1.10 SWITZERLAND
17.1.11 NETHERLANDS
17.1.12 POLAND
17.1.13 IRELAND
17.1.14 NORWAY
17.1.15 LITHUANIA
17.1.16 REST OF EUROPE
18 EUROPE PTERYGIUM DRUG MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILES
20.1 ALCON
20.1.1 COMPANY SNAPSHOT
20.1.2 RECENT FINANCIALS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 ABBVIE INC.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 BAUSCH & LOMB INCORPORATED
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 JOHNSON & JOHNSON SERVICES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 BAYER AG
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENTS
20.6 NOVARTIS AG
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 SANTEN PHARMACEUTICAL CO., LTD.
20.7.1 COMPANY SNAPSHOT
20.7.2 RECENT FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENT
20.8 AKORN OPERATING COMPANY LLC
20.8.1 COMPANY SNAPSHOT
20.8.2 PRODUCT PORTFOLIO
20.8.3 RECENT DEVELOPMENT
20.9 AMNEAL PHARMACEUTICALS LLC.
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 EYERIS VISIONCARE PVT. LTD.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 MAYA BIOTECH PRIVATE LIMITED
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 OASIS MEDICAL
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 PRESTIGE CONSUMER HEALTHCARE INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 SAGER PHARMA
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENTS
20.15 SIMILASAN CORPORATION
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 SPECTRA VISION CARE
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 SYLENTIS
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENT
20.18 THÉA LABORATORIES
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENTS
20.19 WELLONA PHARMA
20.19.1 COMPANY SNAPSHOT
20.19.2 PRODUCT PORTFOLIO
20.19.3 RECENT DEVELOPMENTS
20.2 ZYDUS GROUP
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表格列表
TABLE 1 EUROPE PTERYGIUM DRUG MARKET, PIPELINE ANALYSIS
TABLE 2 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 EUROPE PROGRESSIVE PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 EUROPE ATROPHIC PTERYGIUM IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 EUROPE PTERYGIUM DRUG MARKET , BY STAGES, 2020-2029 (USD MILLION)
TABLE 6 EUROPE STAGE 2 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 EUROPE STAGE 3 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 EUROPE STAGE 1 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 EUROPE STAGE 4 IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 11 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 EUROPE STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 EUROPE STEROID EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 EUROPE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 17 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 19 EUROPE EYE OINTMENTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 22 EUROPE PRESCRIPTION IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 EUROPE OVER THE COUNTER (OTC) IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 25 EUROPE GERIATRICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 EUROPE ADULTS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 EUROPE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 28 EUROPE HOSPITALS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 EUROPE SPECIALTY CLINICS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 EUROPE HOME HEALTHCARE IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 33 EUROPE RETAIL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 EUROPE HOSPITAL PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 EUROPE ONLINE PHARMACIES IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 EUROPE OTHERS IN PTERYGIUM DRUG MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 EUROPE PTERYGIUM DRUG MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 38 EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 39 EUROPE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 40 EUROPE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 41 EUROPE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 EUROPE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 EUROPE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 EUROPE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 45 EUROPE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 46 EUROPE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 47 EUROPE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 48 EUROPE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 EUROPE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 RUSSIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 51 RUSSIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 52 RUSSIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 53 RUSSIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 RUSSIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 RUSSIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 RUSSIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 57 RUSSIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 58 RUSSIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 59 RUSSIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 60 RUSSIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 61 RUSSIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 62 SPAIN PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 63 SPAIN PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 64 SPAIN PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 65 SPAIN ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SPAIN STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 SPAIN KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 SPAIN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 69 SPAIN EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 70 SPAIN PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 71 SPAIN PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 72 SPAIN PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 73 SPAIN PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 74 TURKEY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 75 TURKEY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 76 TURKEY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 77 TURKEY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 TURKEY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 TURKEY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 TURKEY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 81 TURKEY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 82 TURKEY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 83 TURKEY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 84 TURKEY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 TURKEY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 86 GERMANY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 87 GERMANY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 88 GERMANY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 89 GERMANY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 GERMANY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 GERMANY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 GERMANY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 93 GERMANY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 94 GERMANY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 95 GERMANY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 96 GERMANY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 97 GERMANY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 ITALY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 ITALY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 100 ITALY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 101 ITALY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ITALY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ITALY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ITALY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 105 ITALY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 106 ITALY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 107 ITALY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 108 ITALY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 ITALY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 U.K. PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 111 U.K. PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 112 U.K. PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 113 U.K. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 U.K. STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 U.K. KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 U.K. PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 117 U.K. EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 118 U.K. PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 119 U.K. PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 120 U.K. PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 121 U.K. PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 122 FRANCE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 123 FRANCE PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 124 FRANCE PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 125 FRANCE ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 126 FRANCE STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 127 FRANCE KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 FRANCE PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 129 FRANCE EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 130 FRANCE PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 131 FRANCE PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 132 FRANCE PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 133 FRANCE PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 134 HUNGARY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 135 HUNGARY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 136 HUNGARY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 137 HUNGARY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 HUNGARY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 HUNGARY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 HUNGARY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 141 HUNGARY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 142 HUNGARY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 143 HUNGARY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 144 HUNGARY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 145 HUNGARY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 146 AUSTRIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 147 AUSTRIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 148 AUSTRIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 149 AUSTRIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 AUSTRIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 AUSTRIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 AUSTRIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 153 AUSTRIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 154 AUSTRIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 155 AUSTRIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 156 AUSTRIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 157 AUSTRIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 158 SWITZERLAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 159 SWITZERLAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 160 SWITZERLAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 161 SWITZERLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 SWITZERLAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 SWITZERLAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 SWITZERLAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 165 SWITZERLAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 166 SWITZERLAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 167 SWITZERLAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 168 SWITZERLAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 169 SWITZERLAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 NETHERLANDS PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 171 NETHERLANDS PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 172 NETHERLANDS PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 173 NETHERLANDS ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 NETHERLANDS STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 NETHERLANDS KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 NETHERLANDS PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 177 NETHERLANDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 178 NETHERLANDS PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 179 NETHERLANDS PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 180 NETHERLANDS PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 181 NETHERLANDS PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 182 POLAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 183 POLAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 184 POLAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 185 POLAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 POLAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 POLAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 POLAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 189 POLAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 190 POLAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 191 POLAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 192 POLAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 193 POLAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 194 IRELAND PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 195 IRELAND PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 196 IRELAND PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 197 IRELAND ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 198 IRELAND STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 199 IRELAND KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 IRELAND PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 201 IRELAND EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 202 IRELAND PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 203 IRELAND PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 204 IRELAND PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 205 IRELAND PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 206 NORWAY PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 207 NORWAY PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 208 NORWAY PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 209 NORWAY ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 210 NORWAY STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 211 NORWAY KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 212 NORWAY PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 213 NORWAY EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 214 NORWAY PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 215 NORWAY PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 216 NORWAY PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 217 NORWAY PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 218 LITHUANIA PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 219 LITHUANIA PTERYGIUM DRUG MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 220 LITHUANIA PTERYGIUM DRUG MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 221 LITHUANIA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 LITHUANIA STEROIDS EYE DROPS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 LITHUANIA KETONE STEROIDS IN PTERYGIUM DRUG MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 224 LITHUANIA PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 225 LITHUANIA EYE DROPS IN PTERYGIUM DRUG MARKET, BY FORMULATION, 2020-2029 (USD MILLION)
TABLE 226 LITHUANIA PTERYGIUM DRUG MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION)
TABLE 227 LITHUANIA PTERYGIUM DRUG MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)
TABLE 228 LITHUANIA PTERYGIUM DRUG MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 229 LITHUANIA PTERYGIUM DRUG MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 230 REST OF EUROPE PTERYGIUM DRUG MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 2 EUROPE PTERYGIUM DRUG MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE PTERYGIUM DRUG MARKET: DROC ANALYSIS
FIGURE 4 EUROPE PTERYGIUM DRUG MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE PTERYGIUM DRUG MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE PTERYGIUM DRUG MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE PTERYGIUM DRUG MARKET: DBMR POSITION GRID
FIGURE 8 EUROPE PTERYGIUM DRUG MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE PTERYGIUM DRUG MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE PTERYGIUM DRUG MARKET: SEGMENTATION
FIGURE 11 ASIA-PACIFIC IS ANTICIPATED TO DOMINATE THE PTERYGIUM DRUG MARKET AND GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND RISE IN GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE EUROPE PTERYGIUM DRUG MARKET FROM 2022 TO 2029
FIGURE 13 PROGRESSIVE PTERYGIUM SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE EUROPE PTERYGIUM DRUG MARKET FROM 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE PTERYGIUM DRUG MARKET
FIGURE 15 AGEING POPULATION IN THE WORLD (IN MILLIONS)
FIGURE 16 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2021
FIGURE 17 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 18 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, 2021
FIGURE 21 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, 2022-2029 (USD MILLION)
FIGURE 22 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 23 EUROPE PTERYGIUM DRUG MARKET: BY STAGES, LIFELINE CURVE
FIGURE 24 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, 2021
FIGURE 25 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 26 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 27 EUROPE PTERYGIUM DRUG MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 28 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, 2021
FIGURE 29 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, 2022-2029 (USD MILLION)
FIGURE 30 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, CAGR (2022-2029)
FIGURE 31 EUROPE PTERYGIUM DRUG MARKET: BY FORMULATION, LIFELINE CURVE
FIGURE 32 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2021
FIGURE 33 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION)
FIGURE 34 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, CAGR (2022-2029)
FIGURE 35 EUROPE PTERYGIUM DRUG MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 36 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2021
FIGURE 37 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)
FIGURE 38 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, CAGR (2022-2029)
FIGURE 39 EUROPE PTERYGIUM DRUG MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 40 EUROPE PTERYGIUM DRUG MARKET: BY END USER, 2021
FIGURE 41 EUROPE PTERYGIUM DRUG MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 42 EUROPE PTERYGIUM DRUG MARKET: BY END USER, CAGR (2022-2029)
FIGURE 43 EUROPE PTERYGIUM DRUG MARKET: BY END USER, LIFELINE CURVE
FIGURE 44 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 45 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 46 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 47 EUROPE PTERYGIUM DRUG MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 48 EUROPE PTERYGIUM DRUG MARKET: SNAPSHOT (2021)
FIGURE 49 EUROPE PTERYGIUM DRUG MARKET: BY COUNTRY (2021)
FIGURE 50 EUROPE PTERYGIUM DRUG MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 EUROPE PTERYGIUM DRUG MARKET: BY COUNTRY (2021 & 2029)
FIGURE 52 EUROPE PTERYGIUM DRUG MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 EUROPE PTERYGIUM DRUG MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
